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Statement of Translational Relevance 30 
This investigation of the niclosamide prodrug nanoparticle as a potential treatment for 31 
osteosarcoma (OS) represents a foundation for additional preclinical and clinical studies. In the 32 
drug development arena, the ability of the prodrug nanoparticle to significantly increase the 33 
bioavailability of a previously potent, but clinically unusable drug, marks a significant 34 
advancement in the conversion of niclosamide to clinical use. Furthermore, the formulation may 35 
be useful for other hydrophobic drugs that have stagnated in preclinical testing due to poor 36 
bioavailability and limited in vivo stability, despite promising in vitro results. In the 37 
chemotherapy arena, the NSPT demonstrates efficacy against multiple human and canine OS cell 38 
lines and different signaling pathways. Given the challenges in developing targeted therapies for 39 
OS and other genetically heterogeneous tumors, NSPTs in particular may have potential utility 40 
for an effective treatment that avoids the toxicity that has challenged OS patient populations both 41 
during and after current standard-of-care cytotoxic therapies.  42 
  43 
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Abstract  44 
Therapeutic advances for osteosarcoma (OS) have stagnated over the past several decades, 45 
leading to an unmet clinical need for patients. The purpose of this study was to develop a novel 46 
therapy for OS by reformulating and validating niclosamide, an established anthelminthic agent,  47 
as a Niclosamide Stearate Prodrug Therapeutic (NSPT). We sought to improve the low and 48 
inefficient clinical bioavailability of oral dosing, especially for the relatively hydrophobic classes 49 
of anti-cancer drugs. Nanoparticles were fabricated by rapid-solvent shifting and verified using 50 
dynamic light scattering and UV-vis spectrophotometry. NSPT efficacy was then studied in vitro 51 
for cell-viability, cell-proliferation, intracellular-signaling by western blot; ex vivo pulmonary 52 
metastatic assay model; and in vivo PK and lung mouse metastatic model of OS. NSPT 53 
formulation stabilizes niclosamide stearate against hydrolysis and delays enzymolysis; increases 54 
circulation in vivo with t1/2 ~5 h; reduces cell-viability and cell-proliferation in human and canine 55 
OS cells in vitro at 0.2 – 2 µM IC50; inhibits recognized growth pathways, and induces apoptosis 56 
at 20µM; eliminates metastatic lesions in the ex-vivo lung metastatic model; and, when injected 57 
intravenously (i.v.) at 50mg/kg weekly, it prevents metastatic spread in the lungs in a mouse 58 
model of OS over 30 days. In conclusion, niclosamide was optimized for preclinical drug 59 
delivery as a unique prodrug nanoparticle injected i.v. at 50mg/kg (1.9mM). This increased 60 
bioavailability of niclosamide in the blood stream prevented metastatic disease in the mouse. 61 
This chemotherapeutic strategy is now ready for canine trials, and if successful, will be targeted 62 
for human trials in OS patients.  63 
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1. Introduction 64 
1.1 OS has seen almost no chemotherapeutic advances over the past three decades 65 
OS is the most common primary bone malignancy in humans. It most frequently occurs in 66 
adolescence (Friebele, Peck et al. 2015). At presentation, 15 – 20% of patients already have 67 
visible pulmonary metastatic disease, and a majority of patients have lung metastases that are not 68 
yet detectable (Taran, Taran et al. 2017). Because most patients without visible metastatic 69 
disease at presentation likely have undetectable micro-metastasis, systemic therapy - both 70 
neoadjuvant and adjuvant therapy – is a critical addition to surgical resection (Biermann, Chow 71 
et al. 2017). Sadly, OS, unlike most other solid tumors, has seen relatively few chemotherapeutic 72 
advances over the past three decades, particularly with respect to patients presenting with 73 
advanced or metastatic disease (Kager, Zoubek et al. 2003, Mialou, Philip et al. 2005, Aljubran, 74 
Griffin et al. 2009, Mirabello, Troisi et al. 2009, Crawford 2013). Indeed, OS is one of the only 75 
types of cancer for which the prognosis given today is nearly identical to the prognosis given in 76 
1988 (Kansara, Teng et al. 2014). Furthermore, the standard-of-care chemotherapy regimen of 77 
Methotrexate, Adriamycin (doxorubicin), and cis-Platin (MAP) is based on cytotoxic agents 78 
associated with substantial treatment-derived morbidity (Ferrari, Ruggieri et al. 2012, Whelan, 79 
Bielack et al. 2014, Marina, Smeland et al. 2016). Although chemotherapeutic sequela can 80 
prematurely delay or abort treatment regimens in pediatric and adolescent patients, more severe 81 
complications such as anthracycline-induced cardiomyopathy greatly increase subsequent 82 
morbidity (Nagarajan, Kamruzzaman et al. 2011, Taran, Taran et al. 2017). Indeed, even OS 83 
survivors do not have a normal life expectancy due to the morbidity from their adolescent 84 
therapy. Given the extensive toxicity of these agents, there is a critical need to identify new 85 
therapeutics with lower systemic-toxicity and greater efficacy to treat OS with better outcomes 86 
and less treatment-derived morbidity.  87 
 88 
1.2 Repurposing Niclosamide for anti-cancer applications 89 
Since around 2010, there has been a steady rise in popularity of studies investigating niclosamide 90 
for a range of diseases (Kadri, Lambourne et al. 2018), including Parkinson’s, diabetes, bacterial 91 
and viral infections, and cancer. Niclosamide, an FDA-approved anthelmintic (Perera, Western 92 
et al. 1970, WHO 2017), has recently attracted considerable interest as a novel antitumor agent 93 
(Jin, Lu et al. 2010, Osada, Chen et al. 2011, Pan, Ding et al. 2012, Arend, Londoño-Joshi et al. 94 
2013, Londono-Joshi, Arend et al. 2014). Pharmaceutically, niclosamide has been shown to be a 95 
very “dirty drug”; it inhibits (at least) 17 different pathways in cancer cells (Pan, Ding et al. 96 
2012, Li, Li et al. 2014). In the context of OS, niclosamide inhibits multiple pathways that 97 
promote survival and growth that are known to be dysregulated in OS, including the Wnt/ß-98 
catenin, Akt/mTOR/PI3K, JAK/STAT, NOTCH, and NF-B pathways (Chen, Wang et al. 2009, 99 
Arend, Londoño-Joshi et al. 2013, Li, Li et al. 2014, Ahmed, Shaw et al. 2016, Suliman, Zhang 100 
et al. 2016).   101 
In vitro studies have shown that niclosamide induces cell cycle arrest in G1/G0 with cell viability 102 
IC50s in the 100s of nM to low μM range (Arslanagic, Hervella et al. 2016, Arslanagic-Kabiljagic 103 
2019, Karimi 2019 (exp)).  In fact, in vitro studies of niclosamide with the NCI-60 human cancer 104 
cell lines indicate that niclosamide inhibits cell growth in all tested cancer cell lines (NCI 2014). 105 
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In OS, niclosamide also inhibits cell cycle progression (Li, Yu et al. 2015, Liao, Nan et al. 2015), 106 
and one of its main mechanisms of cell death seems to be induction of apoptosis (So Jung, lt et 107 
al. 2011, Ye, Xiong et al. 2014, Li, Yu et al. 2015). With limited formulations for preclinical 108 
evaluation, few studies have been conducted with this drug against cancer in vivo. Importantly 109 
though, in direct contrast to conventional chemotherapies, in vitro, niclosamide is relatively non-110 
toxic to healthy cells [22], including fibroblasts, normal mammary epithelial cells (MCF-10A), 111 
and peripheral blood mononuclear cells (PBMCs) (Osada, Chen et al. 2011), and shows no 112 
evidence of causing developmental toxicity, mutagenicity or carcinogenicity when taken orally 113 
(EPA 1999). Indeed, few, if any, anti-cancer compounds exhibit such a low-toxicity/high-114 
efficacy profile and hit so many different cell targets.   115 
 116 
1.3 Inefficient Clinical Bioavailability of Oral Dosing 117 
One of the most important problems in drug delivery to tumors remains is the low and inefficient 118 
clinical bioavailability of oral dosing, especially for the many hydrophobic classes of anti-cancer 119 
drugs. This is compounded by the fact that there is a dearth of truly-effective formulation options 120 
even for preclinical validation that provide high-plasma-concentration-dosing.  What is needed 121 
for any preclinical validation is an i.v. injectable formulation that puts considerable bioavailable 122 
amounts of such drugs in the circulation. Only then can the highly insoluble drug (in our case 123 
niclosamide) reach the cancer cells by one or more of several mechanisms and have its intended 124 
effects in vivo.  125 
For example, in its anthelmintic application, niclosamide is taken orally at doses as much as two 126 
grams per patient (veterinary or human) (WHO 2002) and has acute oral LD50 values of >1000 127 
mg/kg (Toxicity Category III, slightly toxic and slightly irritating). Niclosamide is a BCS class II 128 
drug, meaning it has poor water solubility (4 M at pH 7.4, (Ebbesen MF 2019)) and its 129 
intestinal absorption is rate-limited by dissolution. Due to this inherently poor aqueous solubility 130 
niclosamide has an extremely low systemic bioavailability in the blood stream and thus has 131 
extremely low bioavailability that hampers its repurposing in cancer.  132 
Experience with its oral formulation for worms and consideration of its physicochemical 133 
properties (logP 4.5, Sw 4 M) suggests that, in its current tablet-formulation, it is actually not 134 
suitable for clinical administration for cancer in order to achieve efficacious results. Indeed, in a 135 
recent human prostate-cancer clinical trial  the short-lived plasma concentrations that were 136 
achieved at the maximum oral-dosing (500 mg given three-times-daily) were only in the range, 137 
35.7 - 82 ng/mL (0.1 – 0.25 M) (Schweizer, Haugk et al. 2018). These values that were only 138 
~0.014% of the ingested dose were below the therapeutic threshold of 0.5 M for colony 139 
formation, as measured for LNCaP prostate cancer cell studies in vitro (Liu, Lou et al. 2015). 140 
Clinically, there were no PSA declines in any enrolled subject and the Data Safety Monitoring 141 
Board closed the study for futility. Similarly, in a new on-going clinical phase I study in patients 142 
with resectable colon cancer (Morse 2017), niclosamide is still being given as the low-143 
bioavailability oral formulation; it is likely to be a very successful Phase 1 toxicity study, but, in 144 
view of the earlier prostate-cancer clinical trial (Schweizer, Haugk et al. 2018), efficacy may 145 
well be compromised. Finally, early results reported in a very recent ASCO abstract (Burock, 146 
Daum et al. 2018) of a prospective phase II clinical trial of niclosamide in patients with 147 
metastasized colorectal cancer (mCRC) (Burock, Daum et al. 2018) progressing under standard 148 
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therapy (NIKOLO) indicate that an oral dosing of two grams per patient can achieve median Cmax 149 
plasma levels of 0.665 µg/ml (~2 While encouraging, these are still relatively modest levels 150 
that are comparable only to IC50s for cell viability.  Importantly, no drug-related toxicities were 151 
observed. Thus, the biggest challenge for repurposing niclosamide for cancer is not toxicity, but 152 
delivery. The drug must be made much more bioavailable in the blood stream and have a more 153 
effective pharmacokinetic profile, including higher plasma-bioavailability concentration and 154 
circulation half-life. 155 
 156 
1.4 Reformulation of Niclosamide as a Niclosamide Stearate Prodrug Therapeutic (NSPT) 157 
Since all clinical niclosamide has only been dosed orally, the maximum tolerated dose (MTD) 158 
has never been determined by i.v. administration directly to the blood stream. Thus, we sought to 159 
identify the i.v.-injectable MTD and determine what doses of niclosamide could be directly 160 
delivered to cancer cells to improve efficacy in early stage metastatic disease. To do this, we 161 
have formulated niclosamide as new Niclosamide Stearate Prodrug Therapeutic (NSPT) 162 
(Needham, Arslanagic et al. 2016, Walke, Hervella et al. 2017, Walke 2018, Hervella, Walke et 163 
al. 2019). Using this nanoparticle formulation, we have started to address some of the main 164 
issues of how to increase the bioavailability of Biopharmaceutical Classification System (BCS) 165 
Class II and IV (Mehta 2016) anti-cancer drugs and enable effective validation in preclinical 166 
studies, and for subsequent canine (Eward, Steve et al. 2018) and human clinical trials.  167 
Current alternative formulations of niclosamide in preclinical development may be hampered by 168 
low percent loading (particularly in micelle and many polymer particles), low dosing, low in vivo 169 
bioavailability, and inefficient access to the tumor interstitium due to large particle size when 170 
tested in vivo (Supplemental 1.5). To avoid the low bioavailability route of oral uptake and to 171 
improve on existing compromised formulations, nanoparticles are needed that 1) enable direct 172 
intravenous injection to increase bioavailability and 2) deliver more drug per particle into the 173 
blood stream.   174 
 175 
2. Materials and Methods 176 
2.1 Materials 177 
Niclosamide stearate prodrug therapeutics (NSPTs) were created using the following materials 178 
and suppliers: niclosamide stearate was synthesized by the Duke Small Molecule Synthesis 179 
Facility (https://sites.duke.edu/smsf/facility-overview/); niclosamide anhydrous (Sigma Aldrich, 180 
Steinheim, Germany), chloroform stock solutions (DSPC, cholesterol, and DSPE PEG
2000
; 181 
Avanti Polar Lipids, Inc., Alabaster, AL, USA), acetone (≥ 99.8 %; Sigma Aldrich, Steinheim, 182 
Germany), absolute ethanol (≥ 99.8 %; VWR Chemicals, Paris, France), chloroform (Rathburn 183 
Chemicals Ltd., Walkerburn, UK), buffer solution components (hydrochloric acid, sodium 184 
chloride, sodium hydroxide; VWR Chemicals, Paris, France), acetic acid (Fluka, Munich, 185 
Germany), sodium phosphate monobasic (Sigma Aldrich, Steinheim, Germany), and Millipure 186 
water. 187 
 188 
2.2 Preparation of Niclosamide Stearate Prodrug Therapeutic (NSPTs).  189 
on May 14, 2020. © 2020 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 




As briefly described (Walke, Hervella et al. 2017) and in more detail (Walke 2018, Hervella, 190 
Walke et al. 2019), the Niclosamide Stearate Prodrug Therapeutic (NSPT) nanoparticles were 191 
made by adapting a rapid solvent-exchange method, (Zhigaltsev 2012, Needham, Arslanagic et 192 
al. 2016) to a new prodrug, niclosamide stearate (Needham, Arslanagic et al. 2016, Walke 2018, 193 
Hervella, Walke et al. 2019). In this method, an organic solution of niclosamide stearate and 194 
lipids (DSPC, Cholesterol, and DSPE-PEG
2000
 in a 45:50:5 ratio) were mixed in a 1:1 equivalent 195 
molar ratio in acetone-ethanol and rapidly injected into an excess anti-solvent of ultrapure water. 196 
Following classical nucleation theory (Karthika, Radhakrishnan et al. 2016), rapid precipitation 197 
spontaneously generates nanoparticles consisting of a core of niclosamide stearate coated with a 198 
monolayer of the lipids suspended in a mainly aqueous phase, containing 10% of the initial 199 
acetone-ethanol solvents (Needham, Arslanagic et al. 2016, Walke, Hervella et al. 2017, Walke 200 
2018, Hervella, Walke et al. 2019). The size of particles (hydrodynamic diameter) was measured 201 
using a Dynamic Light Scattering instrument (Dyna Pro Nanostar, Wyatt Technology, Santa 202 
Barbara, CA).  The NSPT suspension was stored at 4 
o
C until use. The concentration prior to use 203 
was verified using UV spectrophotometry (SpectraMax, Molecular Devices, San Jose, CA) by 204 
measuring the calibrated absorbance of niclosamide-stearate at 330 nm (See Supplemental 2.2 205 
for detailed low- and high- dosing protocols). 206 
 207 
2.3 In-Vitro Stability of NSPT in PBS and Plasma  208 
The chemical stability of NSPT, i.e. hydrolysis of niclosamide-stearate to produce niclosamide 209 
was investigated by 37 
o
C incubation of 1.8 mM NSPT in (1) PBS, (2) mouse, and (3) human 210 
plasma (K2EDTA). A set of 3 aliquots per time-point of each medium was prepared on ice, 211 
placed into pre-equilibrated rack/water bath in 37 
o
C incubator, and aliquots taken from 212 
incubator and placed on dry ice at: 1 min (“zero”), 15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h. 213 
Concentration of both niclosamide-stearate and niclosamide was measured by HPLC as 214 
described below.      215 
 216 
2.4 Pharmacokinetics (PK) of NSPTs 217 
Analysis of chemical composition were performed by high-performance liquid chromatography 218 
(HPLC) for niclosamide and niclosamide stearate up to 24 hours after incubation in PBS buffer, 219 
mouse and human plasma, and serially drawn blood samples from  inoculated mice (S2.4.1 and 220 
S2.4.2). PK parameters (e.g. Cmax, tmax, t1/2, AUC) were calculated by non-compartmental 221 
approach within WinNonlin software (Pharsight Inc.). 222 
 223 
2.5 Cell Culture  224 
Human OS 143B, U2OS, MG63, and SAOS2 cells were obtained from the Duke Cell Culture 225 
Facility, which performs routine mycoplasma testing and verifies cell identity by analysis of 226 
short tandem repeats. Canine OS Abram’s, D17, and Moresco cell lines were provided courtesy 227 
of Dr. Doug Thamm, V.M.D. Colorado State University. The canine OS D418 cell line was 228 
developed from a canine OS patient-derived xenograft (Somarelli, Altunel et al. unpublished). 229 
The 143B, MG-63, D418, Abrams, D17, and Moresco cells were cultured in standard Dulbecco’s 230 
Modified Eagle’s Medium (Thermo-Fisher, Waltham, MA) and the U2OS and SAOS2 lines in 231 
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McCoy’s 5A Modified Medium (Thermo-Fisher, Waltham, MA). Cells were passed every 2-4 232 
days and were not allowed to reach full confluence. 233 
 234 
2.6 Dose-Response Assays of NSPTs on Canine OS Growth.  235 
Dose-dependent effects of NSPTs on all human and canine OS cell-line-growth were determined 236 
using a dose-response CellTiter-Glo assay (Promega Corporation, Madison, WI, USA). To do 237 
this, 2,500 cells were seeded per well in flat bottomed 96-well plates. 100 µL of media 238 
containing either niclosamide in DMSO or NSPTs was added at increasing concentrations (1.6 239 
nM, 8 nM, 40 nM, 200 nM, 1 µM, 5 µM, 25 µM, and 100 µM). Data were compared to a buffer 240 
(no drug) control. Cells were incubated at 37 C for 72 hours and then their cell-viability was 241 
assessed using the CellTiter-Glo substrate metabolic end-point assay (Promega, Madison, WI) by 242 
addition of 50 µL/well of the CellTiter-Glo substrate. Luminescence was measured with 243 
SpectraMax M-series Microplate Reader (Molecular Devices, San Jose, CA). Signal was 244 
normalized to the average of untreated (PBS control) wells. 245 
 246 
2.7 Western Blot Analysis of Canine Cell Lines.  247 
The ability of NSPTs to modulate signaling pathways known to be dysregulated in OS was 248 
investigated by western blotting. A total of 300,000 cells/well of the human OS cell line 143B 249 
and patient-derived canine xenograft (D418) cell line were plated and subsequently incubated 250 
with a concentration of Niclosamide or NSPTs that were known, from the viability assays, to be 251 
on the order of the amount required to reduce cell-viability to almost zero.  As shown in the 252 
results of the cell viability assay, (shown later in Figure 3) this value was at least 20 µM 253 
Niclosamide or NSPT.   Cells were therefore incubated for 0, 1, 2, 4, and 8 hours with 20 µM 254 
Niclosamide or NSPT. Cytosolic and nuclear fractions of lysates at intermediate timepoints were 255 
extracted with Radioimmunoprecipitation assay (RIPA) lysis buffer and the Nuclear/cytoplasmic 256 
extraction reagent (NE-PER)  (Thermo-Fisher, Waltham, MA). Halt Protease and Phosphatase 257 
Inhibitor Cocktail was added to both lysis buffers for a final concentration of 2X. Cell lysates 258 
were centrifuged at 16,000 g at 4 C for 15 minutes. Lysate was separated via Nu PAGE 4-12% 259 
Bis-Tris SDS-PAGE and transferred onto nitrocellulose membranes. After blocking with 260 
Superblock (TBS) Blocking buffer (Thermo-Fisher, Waltham, MA), membranes were incubated 261 
with primary antibody overnight at 4 C and secondary antibody for 1 hour at room temperature. 262 
Primary antibodies included anti-pS6 ser235/236 (clone 91B2, 1:1000), anti-S6 (clone 54D2, 263 
1:1000), anti-Notch1 (clone D1E11, 1:1000), anti-Akt (pan) (clone 11E7, 1:1000), anti-pSTAT3 264 
tyr705 (clone D3A7, 1:2000), anti-Histone H3 (clone D1H2, 1:2000), anti-ß-catenin (clone 265 
L87A12, 1:1000), anti-pAkt Ser473 (clone 193H12, 1:1000), and anti-STAT3 (clone 123H6, 266 
1:1000) (Cell Signaling Technology, MA). Loading controls included anti-GAPDH (1:5000) 267 
(Abcam, MA) and anti-alpha tubulin (1:5000) (Abcam, MA). IRDye 680 nm and 800 nm 268 
secondary antibodies were purchased from Li-Cor (Lincoln, NE). Blots were imaged with the 269 
Odyssey Fc Imaging System and analyzed using Image Studio software (Li-Cor). Signal was 270 
normalized to GAPDH, alpha-tubulin, or Histone H3 loading controls. 271 
 272 
2.8 Isolation of NLS mCherry-Labeled Human and Canine OS Clones 273 
Nuclear Localizing Signal (NLS) mCherry-labeled 143B human and D418 canine OS cell 274 
reporters were isolated for in vitro multiplexed measurements of the effects of NSPTs on OS 275 
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proliferation and apoptosis. Cells were treated with NSPT at the following concentrations: 1.6 276 
nM, 8 nM, 40 nM, 200 nM, 1 M, 5M, 25M, and 100M. NLS mCherry lentiviral vectors 277 
were constructed by the Viral Vector Core, Duke University School of Medicine. Time- and 278 
dose-response assays of NSPTs on NLS mCherry labeled 143B human and D418 canine OS 279 
cells, representing phase confluence %, used red object fluorescence for cell-count and green 280 
object fluorescence for cell area. OS cell lines were plated at 300,000 cells/well onto 6-well 281 
plates.  Cells were incubated with viral titer (MOI of 5) and polybrene (1:500) for 12 hours. NLS 282 
mCherry OS cell lines were then FACS-sorted on a MoFlo Astrios EQ (Beckman Coulter, Brea, 283 
CA) sorter using Summit software (Cytomation, Fort Collins, CO). Non-transduced lines were 284 
used to determine the fluorescence gating strategy. The upper 50% of NLS mCherry cells were 285 
then sorted and a post-sort analysis confirmed purity. 286 
  287 
2.9 Live-Cell Imaging for Kinetic Determination of Proliferation and Analysis of Apoptosis.  288 
Live-cell imaging assessment of NSPTs’ effects on NLS mCherry labeled human and canine OS 289 
proliferation and apoptosis were performed using the IncuCyte® S3 (Essen BioSciences, Ann 290 
Arbor, MI) with the DEVD-amino acid (Asp-Glu-Val-Asp motif) substrate (IncuCyte® Caspase-291 
3/7 Green Apoptosis Assay Reagent, Essen BioSciences, Ann Arbor, MI). Cells were treated 292 
with the same concentrations of NSPTs (1.6 nM, 8 nM, 40 nM, 200 nM, 1 M, 5M, 25M, 293 
and 100M) for 72 hours. Phase-contrast red and green fluorescence channel images were 294 
acquired every 2 hours. IncuCyte® S3 imaging software was utilized to calculate percent 295 
confluency, total NLS cell red fluorescence area per well, and total caspase green fluorescence 296 
area.  Images were assessed for final plots at 96 hours. 297 
 298 
2.10 Generation of zsGreen-Labeled Human and Canine OS Clones for PuMA.  299 
To label OS cells with zsGreen, a total of 300,000 HEK293T cells were plated onto 6-well plates 300 
in complete DMEM and transfected using Lipofectamine LTX plus at 30% confluence with a 301 
vector-mix consisting of 2.0 µg pCL-Ampho, and 2.0 µg pLCNX2 zsGreen construct DNA 302 
(CloneTech, Mountain View, CA). Human and canine OS cell lines were plated at 300,000 303 
cells/well onto 6-well plates. Viral supernatant was collected off HEK293T cells and transferred 304 
onto adherent mid-log human and canine OS cells using a 0.40 µm CA filter. Transduced human 305 
and canine OS cell lines were selected with 100 µg/mL G418 for 14 days.  306 
 307 
2.11 Ex vivo Pulmonary Metastasis Assay (PuMA).  308 
The ex-vivo Pulmonary Metastasis Assay (PuMA) was utilized as previously described 309 
(Mendoza, Hong et al. 2010, Lizardo and Sorensen 2018) to assess the efficacy of NSPTs to 310 
inhibit the growth of zsGreen-labeled human (143B) and canine (D418) OS cells in the 311 
metastatic pulmonary tumor microenvironment (See Supplemental Text for full description).  312 
 313 
2.12 Determination of NSPT maximum tolerable dose  314 
We attempted to determine the single maximal tolerable dose (sMTD) of NSPT for the i.v. route 315 
(via tail-vein injection). We carried out a step-wise dose increase with one mouse at the lowest 316 
dose and 3 mice per higher doses until any significant impact on mouse behavior was observed 317 
over 24 h. C57BL/6 mice (Jackson Laboratory, Bar Harbour, Maine, US) were injected with a 318 
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volume of 0.1ml or 0.2 mL or 0.25 mL per dose. At the time of this study, we had not observed 319 
any toxicity with an injection of 200 L (0.2 mL) of a 100 µM concentrated suspension of 320 
NSPTs (low dose study (Kerr 2017, Kerr, Mikati et al. 2017)), and so 1 mM NSPT was selected 321 
to be the starting injected dose . Again, at the time, the highest achievable dose of the NSPT 322 
preparation was 6 mM, and so single 0.1 mL injections of 1 mM and 6mM NSPT were 323 
administered to give approximate dosing of 3 mg/kg and 20 mg/kg respectively.  Higher target-324 
doses of 36 mg/kg and 47 mg/kg were achieved by increasing the volume of injection of the 325 
6mM suspension to 0.2 mL and 0.25 mL respectively.  A single iv dose of NSPT, that did not 326 
cause significant behavioral change in behavior of all 3 mice was considered tolerated.  As 327 
shown in Results, the highest dose was well tolerated and so this dosing did not actually achieve 328 
a sMTD. 329 
 330 
2.13 Generation of Luciferase-Labeled Human and Canine OS Clones  331 
In order to measure lung-colonization and metastatic tumor growth and development, in vivo, in 332 
the metastatic mouse model over time we generated Luciferase-labeled human and canine OS 333 
clone reporters.  These reporter cells provided an accurate and accessible assessment of in vivo 334 
metastatic tumor burden when animals were administered the luciferin substrate and view by an 335 
In Vivo Imaging System (Caliper Life Sciences, Inc., PerkinElmer, Waltham, MA). Lentiviral 336 
transduction of a luciferase-expressing plasmid was carried out as described above for zsGreen 337 
labeling. PCW-107 was a gift from Dr. Kris Wood, PhD. Equivalent luciferase expressing clones 338 
were selected via the Dual-Luciferase Reporter Assay System (Promega, Madison, WI).  339 
 340 
2.14 Mouse Studies of OS Metastasis at Two NSPT-Dosing Levels  341 
OS tail vein metastasis studies were carried out at two NSPT-dosing levels of 0.59 mg/kg and 50 342 
mg/kg. Luciferase-labeled OS cell lines 143B (Human) and D418 (canine patient-derived) were 343 
cultured as described above. Cells were harvested for injection by trypsinization while in mid-log 344 
phase of growth (50-80% confluence) and concentrated to 5x10
6
 cells/mL in Dulbecco’s 345 
phosphate buffered saline (DPBS). Viability was assessed to be >90% by hemocytometer prior to 346 
inoculation. Cells were kept at 4 °C until inoculation, which occurred within 2 hours of 347 
preparation. Animal studies were performed in accordance with the approved protocols of the 348 
Duke University Institutional Animal Care and Use Committee (IACUC).  349 
In this lung-metastasis model, cells were injected by tail vein injection on “Day 0”, allowed to 350 
reach and start to colonize the lungs for 1 day before NSPT nanoparticles were administered i.v. 351 
again by tail vein injection. The model therefore allowed for direct exposure of OS cancer cells 352 
that were in the very first and early stages of lung colonization These cells were thus likely to be 353 
accessible from the blood stream by the i.v. injection of each 200 µL dose of nanoparticles (0.59 354 
mg/kg or 50 mg/kg). Controls were the same volume of PBS (200 µL) and an intraperitoneal 355 
injection of Doxorubicin, 1.2 mg/kg in PBS.  Thus, on “Day 0”, the OS cell preparations (1x10
6
 356 
cells in 200 µL PBS) were injected directly into the tail veins of 6-week old SCID (Prkdc
scid
) and 357 
beige (Lyst
bg
) mice (Charles River, Wilmington, MA), ~20gms in weight. Then, starting on “Day 358 
1” post-inoculation, mice underwent randomized stratification based on initial pulmonary 359 
seeding luminescence and sex. The total number of mice was 50, consisting of 5 mice in each 360 
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group.  Mice were randomly distributed amongst the following treatment groups: PBS, NSPT, 361 
Doxorubicin (low- and high-dose groupings in Supplemental S2.14.1). 362 
Mice were weighed every 3 days and monitored for signs of morbidity as evidence of presumed 363 
pulmonary metastases or side effects of treatment. Signs monitored included anorexia, 364 
dehydration, dyspnea, diarrhea, lethargy, or decreased grooming activity. In order to produce the 365 
tumor cell-luminescence, prior to imaging, mice were injected intraperitoneally with D-Luciferin 366 
in 200 µL PBS (GoldBio, St. Louis, MO) at 150 mg/kg. In order to determine time-to-peak 367 
luminescence, a kinetic determination of D-Luciferin biodistribution was carried out by serial-368 
imaging mice with known pulmonary disease for 30 minutes following luciferin injection.  369 
Results (Supplementary Figure S5) showed that peak luminescence was obtained within 15 370 
minutes.  Thus, for all subsequent studies, mice were imaged after 15 minutes and the 371 
bioluminescence was captured using the IVIS Lumina XR system (Caliper Life Sciences, Inc., 372 
PerkinElmer, Waltham, MA). Living Image 4.5 software (Caliper) was used to capture the 373 
images and quantify the signal. After mice were euthanized, the thoracic cavities were opened 374 
and lungs were perfused with 10% buffered formalin by tracheal injection using a blunt 375 
perfusion cannula. Lungs were weighed and examined grossly for the number of visible 376 
metastatic lesions on the surface and the left lungs were examined histologically for the number 377 
of internal metastases by sectioning and microscopic examination after H&E staining. Ten non-378 
sequential serial sections were examined per animal.  379 
 380 
2.15 Statistical Analysis 381 
Results are displayed as mean ± standard error of the mean (SEM), unless otherwise indicated. 382 
Luminescence data for the CellTiter-Glo assay that measured ATP and hence cell viability in 383 
dose-response experiments, were plotted on a log[concentration] scale and fitted with 4-384 
parameter logistic curves, IC50 values, and standard errors were calculated from the curve 385 
inflection points. In the 4-parameter logistic model (Sebaugh 2011), the relationship between the 386 
concentration of the drug or prodrug (x) and the cell viability (y), is given by the equation that 387 
includes the “4 parameters”: 388 
𝑥 = 𝑐 (
𝑎−𝑑
𝑦−𝑑
− 1)   Eqn 1 389 
a = the minimum value that can be obtained (i.e. what happens at 0 dose) 390 
d = the maximum value that can be obtained (i.e. what happens at infinite dose) 391 
c = the point of inflection (i.e. the point on the S shaped curve halfway between a and d) 392 
b = Hill’s slope of the curve (i.e. this is related to the steepness of the curve at point c). 393 
One-way ANOVA with Tukey’s post hoc multiple comparisons was utilized for pairwise 394 
comparisons of PuMA lung tumor burden. Wilcoxon pairwise tests were used to compare in vivo 395 
bioluminescence data. Statistical analysis for data analyses were performed with JMP Pro (SAS, 396 
Cary, NC) with a significance level at p < 0.05, unless otherwise indicated. Graphs were plotted 397 
on Prism 7 (GraphPad, La Jolla, CA).  398 
 399 
3. Results 400 
3.1 Size and Stability of NSPTs in Vitro and Pharmacokinetics (PK)/Stability in Vivo  401 
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NSPTs were made for both in vitro and in vivo studies using the established methods of Hervella 402 
et al, (Hervella, Walke et al. 2019). All formulations were evaluated for size stability in water, 403 
and also in non-ionic media including, equiosmotic sucrose or glucose, and isotonic PBS.  404 
Results showed that all NSPT suspensions, as made, were size-stable at 4 
o
C in water, and also in 405 
the non-ionic equiosmotic sucrose or glucose or PBS (See Figure S1A and B, Supplemental 406 
Information). The rapid solvent injection method (Hervella, Walke et al. 2019) gave a 407 
suspension concentration of 100 M for the low-dose sample, and the nanoparticle size 408 
(diameter) directly after making was measured by DLS (intensity mode) to be 30  5 nm, in close 409 
agreement with Hervella et al’s results (Hervella, Walke et al. 2019).   For the up-concentrated 410 
sample, the sizes increased slightly.  For all 5 of the 50 mg/kg treatments the “intensity” average 411 
distribution particle diameter was 45 ± 5 nm. As shown in Figure 1A, the intensity average 412 
distribution for Treatment 1 was 44.7 nm   1.6 nm. Shown in Figure 1 B is a scaled schematic 413 
of a representative 30nm diameter NSPT.  It is shown with a 16.6nm diameter, isotropic, core of 414 
niclosamide stearate and a stabilizing lipid monolayer of DSPC:Chol, containing a coverage of 415 
polyethylene glycol (PEG) provided by 5 mol% of DSPE-PEG
2000
.  Detailed discussion of this 416 
schematic with reference to its critical size and phase-state is reserved for the discussion section.  417 
 418 
The niclosamide-stearate is a niclosamide prodrug in which a fatty acid stearate is covalently 419 
linked to niclosamide by an ester bond. In vivo, the ester bond is expected to be hydrolyzed by 420 
chemical and/or enzymatic hydrolysis, releasing "free" niclosamide. In order to assess the extent 421 
of the hydrolysis and the achieved levels of niclosamide in plasma, we performed a 422 
pharmacokinetic (PK) experiment in mouse whereas 50 mg/kg NSPT was injected i.v. and 423 
plasma collected in time within 24 h. In addition, to learn about the intrinsic stability of NSPT in 424 
solution and plasma and to better understand the obtained PK data, 37 
o
C incubation of NSPT in 425 
PBS, mouse plasma, and human plasma was performed as well.  426 
The Figure 2B shows the PK profiles for NSPT (measured as NS) and NIC, both exhibiting 427 
single exponential decay of the same half-life (t1/2 = 5 h), as calculated from the slope in the log-428 
lin plot (Figure 2B, inset). Dashed line shows the published data obtained after i.v. bolus 429 
administration of NIC to rat (Chang et al. 2006). In this experiment by Chang et al, the 430 
compound was administered intravenously (i.v.) at a dose of 2-mg/kg. The dosing solution was 431 
prepared by dissolving the compound in a mixture of dimethyl sulfoxide (DMSO)/ cremophor 432 
EL/water (3/15/82 v/v/v). Interestingly, compared to the Area Under the Curves (AUC) for our 433 
Niclosamide Stearate (NS) of 3560h*ug/ml and NIC of 690h*ug/ml,  the Chang data (Chang et 434 
al. 2006) shows an AUC of only 1.4 h*ug/ml (2,543 times lower than the NS AUC).  The inset 435 
shows the log-linear plot giving a similar half-life for both NS (5 hrs) and NIC (5.5hrs) by a 436 
single-order decay.  And for comparison with our study, we see that Chang’s direct injection has 437 
a similar half-life of 5.7 hrs albeit at much lower plasma levels.   438 
We dose-adjusted and plotted the data to illustrate the magnitude of the gain in NIC exposure 439 
(AUC) when NIC is administered not in its free form but rather as NSPT (AUCNSPT->NIC/AUCfree 440 
NIC = 470). The NSPT and NIC are of different size and physical properties so the observed PK 441 
profile of the released NIC in plasma may be explained as being rate-controlled by the rate of 442 
NSPT loss from circulation (as observed from similar nano-particles, t1/2 ~7 h, Hervella, Dam et 443 
al. 2018), whereas the magnitude of the NIC plasma concentration is determined by the rate of 444 
NIC production from NSPT by enzymolysis. Indeed, the Figure 2A shows the in-vitro 445 
production of NIC by a mixed order enzymolysis process (fast first-order followed by slower 446 
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zero-order) in mouse plasma as being of the same order of magnitude, t1/2 ranging from 2-13 h. 447 
The Figure 2A also reveals that the rate of enzymolysis in human plasma is very similar as in 448 
mouse plasma, whereas the simple pH-dependent hydrolysis in aqueous solution (PBS) is much 449 
slower as expected for lipid monolayer-protected NSPT core.   450 
 451 
3.3 Cell viability, proliferation, and ATP present in human and canine OS Cells in vitro 452 
NSPTs inhibited cell viability, proliferation, and the quantity of intracellular-ATP present in 453 
human and canine OS Cells in vitro.  As shown in Figure 3A for the human 143B and canine 454 
D418 cell lines, dose response assays demonstrated that both niclosamide (from DMSO) and 455 
NSPTs (added as an aqueous suspension) inhibited in vitro canine and human OS cell-growth in 456 
a dose-dependent manner. (See Supplementary Figure S2A for individual plots of all 8 cell 457 
lines). Also, the dose response for cell viability gave very similar profiles for both the parent 458 
drug niclosamide and the niclosamide stearate prodrug therapeutic nanoparticles for both the 459 
canine and human cells.  460 
 461 
Cumulated in Figure 3B, IC50 values for all cell lines were in the micromolar to sub-micromolar 462 
range, showing, in general, that all cells were slightly more sensitive to Niclosamide from 463 
DMSO when compared to NSPTs (Mean IC50: 0.57 µM vs. Mean IC50: 1.22 µM, respectively; 464 
p=0.002). However, on average, there were no statistically significant differences between 465 
inhibition of human and canine OS cells by niclosamide and NSPTs (Mean IC50: 1.16 µM vs. 466 
Mean IC50: 1.27 µM, respectively; p=0.79). 467 
Figure 3C shows time- and dose-response assays of NSPTs in terms of a proliferation-assay 468 
based on NLS mCherry labeled 143B human and D418 canine OS cells. Figure 3C (i), compares 469 
cell count and cell area representing phase confluence %.  Below about 5 M NSPT, cells 470 
showed increasing confluence and hence proliferation as total red area Figure 3C (ii).  Above 5 471 
M there was a marked dose-dependent inhibition in cell proliferation in both cell lines. When 472 
plotted in Figure 3D, the micromolar IC50  of NSPTs for this live-cell imaging assay of 473 
proliferation (Figure 3A) were similar to the IC50 for the cell viability (ATP based end point) 474 
assay Figure 3C (ii)  for canine OS cells (mean IC50 proliferation 3.46 µM vs. mean IC50 475 
viability: 1.27 µM, respectively; p=0.009), but were somewhat greater for human (Mean IC50 476 
proliferation: 6.74 µM vs. Mean IC50 viability: 0.88 µM, respectively; p=0.17). The green 477 
fluorescence intensity assay (Figure 3C (iii)) measured the response of the cells to NSPTs in 478 
terms of effective apoptosis. Here, the half maximal effective concentrations (EC50s) of NSPTs 479 
on caspase 3/7 facilitated-apoptosis in both 143B and D418 OS cells showed clear evidence of 480 
apoptosis in a dose dependent manner.  (See Supplementary Figure S2B and C for individual 481 
plots of all 8 cell lines) 482 
As shown in the cross plots in Figure 3D, cell proliferation was inhibited with increasing NSPT 483 
addition and the level of measured apoptosis rose.  The EC50s for apoptosis though were 484 
significantly higher than the IC50s for inhibition of proliferation (mean EC50 apoptosis: 20.9 µM 485 
vs. mean IC50 proliferation: 4.868 µM, p=0.04). (See Supplementary Figure S2D for individual 486 
plots of all 8 cell lines).  Time-dependent inhibition of proliferation by NSPTs was noted as 487 
quickly as 4 hours after initiation of treatment in the relatively high concentration, 100 µM, 488 
groups. In these same high concentration, 100 µM, groups Caspase 3/7 mediated apoptosis was 489 
first noted 12 hours after initiation of treatment. Thus, there appears to be a slight non-apoptotic, 490 
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cytotoxic inhibition of OS cells when treated with lower concentrations and at earlier exposure 491 
times. The results of the Western Blots are shown in Figure 3E for both cell lines, as presented 492 
next.  493 
 494 
3.4 NSPTs inhibited multiple human and canine OS signaling pathways 495 
Multiple signaling pathways have been implicated in niclosamide’s growth inhibition of human 496 
and canine OS cells (Pan, Ding et al. 2012), including NF-κB, Wnt/β-catenin, Notch, ROS, 497 
mTORC1, and Stat3, and so we expected, and tested to determine if and to what extent  NSPTs 498 
would do the same. The PI3K/Akt/mTOR/S6 signaling pathway, and particularly the 499 
downstream mammalian target of rapamycin (mTOR) and complex (mTORC1), are important 500 
regulators of cell-cycle progression and are frequently abnormally activated in OS (Ding, 501 
Congwei et al. 2016). Increasing mTOR activity has been shown to drive cell cycle progression 502 
and increase cell proliferation.  Conversely, as was shown in cervical cancer cells (Li, Li et al. 503 
2013), the inhibition of mTOR (by the inhibitor AZD8055, at only 10 nM) inhibits proliferation 504 
and glycolysis, and, again, was found to induce apoptosis in the HeLa cells in a time-dependent 505 
manner. In the same study by Li et al, the phosphorylation of the C1 substrates p70S6K and 506 
phosphorylation of the mTORC2 substrate Akt were deregulated. An inhibition of mTOR in OS 507 
cells could therefore correlate with their reduced proliferation (Figure 3 C).  As shown in Figure 508 
3E, in both 143B (i) and D418 ((ii) NSPTs induced a time-dependent reduction in the 509 
phosphorylated form of S6. Notably, in the D418 cell line, an initial increase in the p-Akt signal 510 
was observed at 1 hour before the signal decreased. The nuclear localization of -catenin 511 
(Figure 3E (iii) was reduced in separate cell lysates in 143B using nuclear/cytoplasmic 512 
fractionation of untreated and treated cells. The presence of nuclear -catenin was also reduced 513 
in the 143B cell lines after 24 hours of treatment with 20 M niclosamide-stearate nanoparticles. 514 
As shown in Supplementary Figure S3A and B for individual plots of all 8 cell lines, nuclear 515 
-catenin also reduced in MG-63, U2OS and SaOS2 cell lines after the same 24 hours of 516 
treatment with NSPT. 517 
Taking all 8 cell lines into consideration, (See Supplementary Figure S3A and B for individual 518 
plots of all 8 cell lines), the amount of phosphorylated Akt did not change over 8 hours in 519 
Abrams and Moresco cell lines. As with the 143B, D418 lines, NSPTs also induced a time-520 
dependent reduction in the phosphorylated form of S6 in MG-63, U2OS, SaOS2, D17, and 521 
Moresco. Phosphorylated STAT3 increased initially in MG-63, U2OS, SaOS2, and D17 before 522 
decreasing at 8 hours, while it was not present at all in the other human and canine OS cells (See 523 
Supplementary Figure S3A and B).  Niclosamide’s inhibition of the Akt/mTOR/S6 pathway is 524 
particularly beneficial, as mTOR/p70S6K has been clinically prognostic of disease-free and 525 
overall survival in patients presenting with primary OS (Zhou, Deng et al. 2010). Regarding the 526 
PI3K/Akt/mTOR/S6 pathway, NSPTs increased phosphorylated Akt but only transiently over the 527 
first two hours. 528 
 529 
3.5 NSPTs decreased ex vivo growth of pulmonary metastases 530 
To interrogate the ability of NSPTs to slow the progression of pulmonary metastases in 143B 531 
human and D418 canine OS cells, we performed an ex vivo Pulmonary Metastasis Assay 532 
(PuMA) (Mendoza, Hong et al. 2010, Lizardo and Sorensen 2018), (See also Supplementary 533 
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Figure S4 for images of lung slices loaded with OS cancer cells prepared ex vivo after 534 
tracheotomy as well as  Bright-field-Fluorescent images of lung metastases in the lung tissues 535 
ex-vivo on Day 1 (400ms exposure) at 5X magnification and a  Higher magnification (40X)  536 
image of fluorescent lung metastases).  PBS control, doxorubicin, or NSPTs, were administered 537 
to the lung slices upon plating out on the day of surgery. The fluorescence results of the PuMA 538 
(quantified as mean fluorescence area/total lung area) are shown in Figure 4. For the PBS 539 
controls, both 143B (A) and D418 (B) cells established bulky, metastatic disease by Day 5 and 540 
continued to develop through Day 10.   541 
 542 
Interestingly, the tumor burden was more prevalent at the initial stages (Day 1 and 5) in the 143B 543 
human cell line as quantified in Figure 4B) than in the D418 canine as quantified in Figure 4D. 544 
For example, on Days 1 and 5 the 143B human cell line showed increasing tumor burden of 545 
0.018, 0.042, while, in contract the D418 tumor burden started out at 0.0125 on Day 1, and only 546 
increased slightly to 0.014 on Day 5.  However, while the 143B on Day 10 had actually reduced 547 
slightly to 0.035, the D418 line increased dramatically to 0.06 by Day 10.  548 
For the drug-treated slices, all dosing (Dox and NSPTs) was, as expected, relatively ineffective 549 
on Day 1. Satisfyingly though, NSPTs, at both 10 µM and 50 µM, were able to completely 550 
reduce the lung tumor burden to undetectable by Day 5 in both 143B human (Figure 4A, B, C) 551 
and D418 canine (Figure 4D, E, F) OS cells. The standard of care chemotherapeutic, 552 
doxorubicin, also significantly inhibited lung tumor burden at 1 µM and 10 µM concentrations, 553 
although, morphologically and quantitatively, there was a higher tumor burden in both cell lines 554 
at Day 5 (Figure 4B and C, D and F respectively)). By day 10, NSPTs continued to show 555 
complete reduction of tumor burden with no evidence of recovery, and the doxorubicin response 556 
had become morphologically and quantitatively similar to NSPT.  557 
Thus, in the ex vivo Pulmonary Metastasis Assay we found that the assay accurately recreated the 558 
growth of 143B human and D418 canine OS cells, (that we had seen for controls in cell culture 559 
media as proliferation (Figure 3Ci)), but now within an actual lung tumor microenvironment. 560 
They also effectively showed the inhibitory effects of NSPTs when dosed in the culture dish 561 
medium through 1-2 mm thick lung parenchyma. Interestingly, the amounts of NSPTs that were 562 
effective in both 143B and D418 cell lines in the PuMA, when related to the IC50s for cell 563 
viability from cell culture (0.71 and 1.6 M), showed that NSPTs (10 M by day 5) were able to 564 
massively inhibit the growth of pulmonary metastases in this model at only 14x and 6x the IC50, 565 
for cell viability (ATP inhibition), respectively.  566 
 567 
3.6 NSPTs administration to determine toxicity 568 
The first feasibility study was carried out at a modest 0.59 mg/kg and no deleterious effects were 569 
seen in the mice in terms of toxicity or regarding weight loss over the first 30 days (Figure 5D), 570 
until they succumbed to the lung metastases.  We therefore decided to increase the dose and 571 
provide some measure of an MTD by carrying out a dose escalation and observing any response 572 
in C57BL/6 mice over 24hrs. As shown in Table 1. Parameters for Dose escalation study, 573 
three dosing levels were tested.  The initial plasma concentrations achieved in the mice were not 574 
measured, but were calculated based on a mouse blood volume of 1mL (Riches, Sharp et al. 575 
1973, NC3Rs 2019).  576 
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An NSPT injection into a C57BL/6 mouse of 100 L of a 1 mM suspension concentration 577 
(equivalent to a 3.21 mg/kg dose and 91 M NSPT in the blood stream), produced no changes in 578 
behavior when followed for 24 hours after injection. Similarly increasing the 100 L injection 579 
concentration to a 6 mM suspension of NSPTs, (providing ~20 mg/kg and a blood concentration 580 
of 541M), also showed no adverse effects during 24hr inspection in the 3 C57BL/6 mice. 581 
Because 6mM NSPTs was a relative upper concentration limit to our preparation at the time 582 
(including ultrafiltration for up-concentration), in order to achieve a higher dose, 200 L, 250 583 
L, and 250 L were injected into each of three subsequent mice (to give 36.81 mg/kg, 45.77 584 
mg/kg, and 47.24 mg/kg, equivalent to blood concentrations of 0.99 mM, 1.19 mM, and 1.19 585 
mM respectively). Again, there were no adverse effects at 24hrs. 586 
  587 
Therefore, the MTD was apparently not reached even at 50 mg/kg with up to 1.19 mM of the 588 
prodrug Niclosamide Stearate (and therefore Niclosamide) in the blood stream.  We therefore 589 
used this much higher dose for the second metastatic assay experiment. The result was, that 590 
NSPTs can be administered to mice at 50mg/kg without discernable toxicity. 591 
 592 
3.7 In vivo studies at two dosings in a mouse model of OS metastasis 593 
Two dosings of NSPTs were trialed. The first dose was at 0.59 mg/kg and was used as a safe and 594 
exploratory feasibility study of the possible effects of the new NSPTs in the lung metastasis 595 
model (Kerr 2017).  Following the dose escalation study, where we had determined that a 596 
50mg/kg dose could be achieved without any discernable toxicity (and so was not even yet the 597 
MTD), the second study was carried out at this dose of 50 mg/kg NSPTs (Reddy 2018).  To 598 
simulate the effect of metastatic disease, mice were inoculated via tail-vein injection with 5 x 10
5
 599 
luciferase-labeled 143B human or D418 canine PDX-derived OS cells (as depicted schematically 600 
in Figure 5E). This injection produced a colonization of the lung with OS cells as disseminated 601 
metastases. Data for each study are now presented below. 602 
3.7.1 NSPTs at 0.59mg/kg low dose study  603 
NSPTs at 0.59 mg/kg prolonged the survival in 143B-bearing mice without the treatment-derived 604 
morbidity shown by Doxorubicin. In the low dose study (Kerr 2017), a cohort of sixteen 12-605 
week-old SCID/beige mice bearing the 143B tumor line were treated in groups with either 606 
weekly i.v. doses of: the control of 200 L PBS; or 200 L doses of niclosamide-stearate 607 
nanoparticles in PBS suspension at a molar concentration of 100 M (0.059 mg/mL); or weekly 608 
intraperitoneal (i.p.) doses of doxorubicin at 1.2 mg/kg in PBS; or combination therapy 609 
(niclosamide-stearate nanoparticles i.v. weekly, doxorubicin i.p. weekly). As shown in Figure 5, 610 
they were followed for 50 days for overall survival, and for 17 days using IVIS imaging to 611 
observe and quantitate tumor burden. Mice were euthanized when they presented with signs of 612 
significant morbidity, such as lethargy or behavioral changes due to the lung metastatic burden. 613 
IVIS images in Figure 5A, representing a typical example of the results, showed that the PBS 614 
control mice rapidly developed lung metastases within 7 days, and by day 16 there was massive 615 
lung tumor burden visible.   616 
 617 
In contrast, both NSPT- and Dox-treated mice showed reduced tumor burden compared to these 618 
controls. However, the NSPT cohort showed consistently less tumor burden than the 619 
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Doxorubicin-treated cohort. This visual data was quantified in Figure 5B, giving the tumor 620 
burden as average bioluminescence in units of Radiance "photons/second/cm
2
/steradian" 621 
(p/s/cm2/sr) (see footnote1). The Dox and NSPT cohorts had a lower bioluminescence than 622 
controls with NSPTs being the least, signifying their lower tumor burden out to day 17.  Thus, in 623 
mice that were inoculated with the human 143B cell line, treatment with niclosamide-stearate 624 
nanoparticles at this first dose of 0.59mg/kg was associated with delayed tumor growth 625 
compared to the saline-treated group, with significantly less tumor burden at 14 and 16 days 626 
(p=0.0367, p=0.020 respectively).  Note: this 0.59 mg/kg dose represents a calculated blood 627 
concentration (based on a mouse weight of 20 g and a 1mL mouse blood volume), of 20 M; this 628 
is 12x the measured cell viability IC50 (of 1.68 M) for this 143B cell line from Figure 3 (see 629 
later in Discussion). 630 
 In the Kaplan-Meier analysis, (Figure 5C), at the point at which all the PBS control mice had 631 
died, NSPT-treated mice were still at 100% survival. The 0.59 mg/kg NSPT treatment, given 632 
only on a weekly basis, prolonged survival with a mean survival of 40 days compared to 30 days 633 
in the PBS group (p=0.0067, Figure 5C). There was actually no statistically significant 634 
difference in survival between the mice treated with niclosamide-stearate nanoparticles, 635 
doxorubicin, or combined therapy. Importantly though for this 143B human cell line, 636 
unfortunately, mice had to be euthanized early for the Doxorubicin cohort. The doxorubicin-637 
treated mice developed diarrhea and weight loss early in the course of therapy (Figure 5D) and 638 
doxorubicin treatment was held for both doxorubicin-only and combined-therapy groups at day 639 
21. The NSPT and PBS treated groups did not demonstrate any early treatment-related side 640 
effects or weight loss out to at least 30 days, until they succumbed to the cancer.  641 
 642 
3.7.2 NSPTs at 50 mg/kg high dose study  643 
NSPTs at 50 mg/kg inhibited metastatic development in D418-bearing mice and safely delayed 644 
tumor progression. In this higher dose study (Reddy 2018), 6-week old SCID/beige mice were 645 
again inoculated via tail-vein injection with luciferase-labeled D418 canine PDX-derived OS 646 
cells (as shown schematically in Figure 5E). (See Supplemental Table S1 for details of each 647 
mouse in the study, showing mouse weight (g), NPST diameter (nm), suspension concentration 648 
(mM), and amount (mg) of NPST injected in each 200 mL to achieve 50mg/kg niclosamide 649 
Stearate (equivalent to 27mg/kg niclosamide) per mouse dosing). 650 
Animals were treated with either the control of phosphate-buffered saline (PBS) or NSPTs by i.v 651 
injection, or doxorubicin intraperitoneally (i.p.). In this experiment, mice were relocated in the 652 
microscopy suite and so bioluminescence by IVIS was measured from Day 0. As shown in 653 
Figure 6B, immediately following inoculation, OS cells were seen to be trapped in the lungs and 654 
                                                 
1 As described by Caliper Life Sciences Inc, Sciences, C. L. (2011). "Image Display and Measurement."   
Retrieved 9th February, 2019, from https://mbi-ctac.sites.medinfo.ufl.edu/files/2017/02/Concept-Tech-Note-2-
Image-Display-and-Measurement.pdf.”the radiance unit of photons/sec/cm2/sr is the number of photons per second 
that leave a square centimeter of tissue and radiate into a solid angle of one steradian (sr). A steradian can be thought 
of as a three-dimensional cone of light emitted from the surface that has a unit solid angle. Much like a radian is a 
unit of arc length for a circle, a steradian is a unit of solid angle for a sphere. An entire sphere has 4π steradians. 
Lens systems typically collect light from only a small fraction of the total 4π steradians”. 
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gave an initial seeding-bioluminescence that was not significantly different between treatment 655 
groups.  656 
 657 
The seeding value decreased rapidly in PBS controls from 34525 ± 24796 p/s/cm2/sr value to 1766 ± 658 
535 p/s/cm2/sr at day 3, presumably, as cancer cells failed to survive and colonize. From day 10 659 
though, the bioluminescence and hence tumor burden rapidly increased reaching levels of 30,000 660 
p/s/cm2/sr, but now representing established metastases in the lungs. Interestingly, based on the IVIS 661 
images, in contrast to the 143B experiment (Figure 5A), control mice inoculated with the same 662 
number (5 x 10
5
 luciferase-labeled) D418 OS cells took longer to develop the lung metastases 663 
(Compare Figure 5A day 16 with Figure 6A day 17).   664 
Importantly, as shown in Figure 6B, the lung tumor burden for mice treated with the NSPTs on 665 
only a weekly basis (Days 1 and 8, 15, 22, 29), began to diverge from the PBS group at Day 9, 666 
and remained at the ~2,000 p/s/cm2/sr bioluminescence baseline-level out to 26 days, before 667 
rising slightly by the endpoint at Day 32. This demonstrated for the first time that weekly dosing 668 
of NSPTs at 50mg/kg prevented the establishment and control metastatic disease in the lungs of 669 
the D418 cells.  The result was even more significant in view of the data that showed this 670 
particular tumor was actually resistant to the standard of care drug, doxorubicin (Figure 6B). 671 
Again, as with the lower 0.59mg/kg dose cohort, NSPT-treated mice at 50mg/kg did not have 672 
any weight loss associated with five weekly doses. Importantly for this drug (niclosamide) that 673 
has shown to be relatively non-toxic in cell studies to healthy cells, even at this relatively large 674 
i.v. 50 mg/kg dose, NSPT-treated mice had significantly greater body weight when compared 675 
against doxorubicin-treated mice, as shown in Figure 6C, and even gained weight while on the 676 




4. Discussion 681 
Taken together, our data suggest NSPT is a novel and effective formulation of niclosamide ready 682 
to undergo further evaluation as a new treatment for OS. Analysis of the potential mechanism of 683 
action of this NSPT pinpointed multiple pathways known to be deregulated in OS. Interestingly, 684 
other literature (Park, Shin et al. 2011, Jurgeit, McDowell et al. 2012, Sukumar and Gopinath 685 
2016, Alasadi, Chen et al. 2018, Childress, Alexopoulos et al. 2018) as well as our own data in 686 
vitro indicate niclosamide, at its most fundamental level, acts by disrupting ATP synthesis.  As 687 
such, this mechanism acts upstream of many of the other processes in the OS cell, since they 688 
require ATP and phosphorylation to operate. Mechanistically, from a medicinal chemistry point 689 
of view, this activity of niclosamide represents a drug target that is not the usual drug-protein (or 690 
-DNA -RNA) macromolecule but may well be action at the lipid membrane level. In support of 691 
this hypothesis niclosamide has been described as a proton shunt in mitochondria, and these 692 
effects induce OS-cell kill by apoptosis (Jurgeit, McDowell et al. 2012, Alasadi, Chen et al. 693 
2018). This brings into play a new kind of medicinal chemistry for drugability, i.e., designing 694 
better lipophilic anions (a delocalized electron in relatively high logP-molecule) capable of even 695 
more efficient membrane partitioning and proton carrier functions to dissipate the pH gradients 696 
in mitochondria, lysozomes and other internal cell organelles that rely on cation gradients.    697 
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Cell signaling studies for active components of the mTOR, Jak/STAT, and Wnt/-catenin 698 
pathways, showed that, in both human and canine OS, NSPTs decreased the phosphorylated 699 
form of S6 (pS6) at 8 hours without any decrease in phosphorylated Akt. The 700 
PI3K/Akt/mTOR/S6 signaling pathway, and particularly the downstream mammalian target of 701 
rapamycin (mTOR) and complex (mTORC1), are important regulators of cell cycle progression 702 
and are frequently activated abnormally in OS (Ding, Congwei et al. 2016). Niclosamide’s 703 
inhibition of the Akt/mTOR/S6 pathway is particularly beneficial, since mTOR functions as a 704 
sensor of mitogen, energy and nutrient levels, and is a central controller of cell growth and a 705 
negative regulator of autophagy. The mTOR/p70S6K axis has been clinically prognostic of 706 
disease-free and overall survival in patients with primary OS (Zhou, Deng et al. 2010). In the 707 
D418 and D17 cell lines, while p-Akt was found to increase with treatment, the downstream 708 
decrease in p-S6 is likely due to direct inhibition of either mTORC1 or p70S6K. 709 
In vivo we observed significant reductions in metastatic burden and improved survival in mice 710 
with metastatic OS at a low dose of just 0.59 mg/kg weekly.  Following this positive “low-dose” 711 
data, we next used a dose of 50mg/kg and found no increase in toxicity. While niclosamide itself 712 
when given orally is extremely safe (WHO 2002)), this is the first time that such a high dose of 713 
50 mg/kg NSPT has been injected i.v., to obtain an initial dosing of 27 mg/kg equivalent 714 
niclosamide.  For this particular drug (niclosamide and the prodrug NSPTs) the issue is therefore 715 
not reducing toxicity, as it is in many chemotherapy applications, but more effective drug 716 
delivery (than oral dosing). Thus, in these experiments and with this NSPT design, the goal of 717 
bioavailable dosing had been achieved and, moreover, the NSPTs were efficacious in preventing 718 
metastatic disease without systemic toxicity.  719 
When compared to the oral dosing in the clinical trial for prostate cancer of Schweizer et al 720 
(Schweizer, Haugk et al. 2018) that gave sub-micromolar plasma concentrations that were not 721 
even close to the in vitro efficacy our high-micromolar values are approximately 10,000 times 722 
the values achieved by oral dosing.  Even in the prospective phase II clinical trial of niclosamide 723 
in patients with metastasized colorectal cancer (mCRC) (Burock, Daum et al. 2018, Burock, 724 
Daum et al. 2018) the median Cmax plasma levels of 0.665 µg/mL (~2 µM), our values for NSPT 725 
are still almost 1,000 times the ones achieved with an oral dosing of 2 g/patient. This shows how 726 
extremely significant is of our new NSPT-based i.v. dosing approach to the cancer treatment by 727 
niclosamide.   728 
We demonstrated here an innovative strategy to engage the principles of medicinal chemistry to 729 
repurpose an old, economical drug.  We managed to optimize it for drug delivery as a unique 730 
nanoparticle formulation (Chen 2016), that increased the bioavailability of niclosamide in the 731 
blood stream (by i.v. injection of the prodrug at 50 mg/kg) and allowed its validation in the 732 
preclinical setting in mice with a well-performing lung metastasis-model of OS. Using 733 
bioluminescent tumor labeling, we were able to study and establish the in vivo efficacy of the 734 
NSPTs in both a human OS cell line (143B) and a canine cell line (D418).  The data suggest that 735 
30 nm diameter NSPTs are both effective and safe in treating simulated metastatic disease for 736 
both human and canine OS in an in vivo mouse model. The NSPT nanoparticles were designed to 737 
be stable against hydrolysis, due to the tight lipid-cholesterol monolayer, and “stealthy”, i.e., 738 
they contained enough DSPE-PEG
2000
 on their surfaces embedded in the DSPC:cholesterol 739 
monolayer that coated the particle to provide a relatively long (6-7hrs) circulation half-life for 740 
the prodrug compound. Currently there are no other options for administering niclosamide i.v.  741 
preclinically except from a direct DMA injection (Bhattacharyya, Ren et al. 2017) which is 742 
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clinically unacceptable. Our pro-drug delivery strategy converted the relatively water-insoluble 743 
niclosamide (Sw = 4M) to its even less soluble (~30nM) stearate ester for the expressed 744 
purpose of making injectable NSPT nanoparticles at doses at least as high as 50mg/kg. This 745 
strategy has successfully transformed a previously unacceptably-low-bioavailable niclosamide 746 
into a customizable and efficacious therapeutic with the requisite pharmacokinetics and 747 
tolerability profile for immediate canine and subsequent human clinical testing. NSPTs are able 748 
to inhibit OS cell growth in several orthogonal modalities (IC50 = 0.2 M – 2 M) and function 749 
as effective prodrug therapeutics in metastatic OS in vivo, leading to decreased metastatic tumor 750 
burden ex vivo and in vivo. Future directions will be multilateral and involve several areas of 751 
interest. Perhaps the most important from a biological and interaction standpoint is further 752 
elucidating the broad mechanisms of NSPTs and indeed niclosamide on OS cells and other solid 753 
tumors. In addition, this would be helpful in then determining an in vivo pharmacokinetic marker 754 
of NSPT action. Different nanoparticle formulations (ligand-targeting, fluorescent tagging, active 755 
immunomodulation, etc.) and combinations with established and candidate chemotherapeutics 756 
and concentrations can be trialed in high throughput in vitro and ex vivo PuMA screens. 757 
Validating a primary orthotopic model that can spontaneously metastasize would then provide 758 
another opportunity to test NSPTs effectiveness in a complementary model. Finally, pilot clinical 759 
testing in canine patients with primary and metastatic OS would provide valuable, actionable 760 
insight into the viability and challenges with NSPT production, drug quality assurance, and 761 
clinical administration and subsequent tolerability observations. From those early clinical 762 
studies, additional clinical studies can be escalated to larger canine, randomized control trials and 763 
human Phase I studies to realize the ultimate goals of improving survival and decreasing 764 
morbidity for OS patients. 765 
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8. Tables 950 
 Dose 1  Dose 2  Dose 3 
 Mouse 1  Mouse 1 Mouse 2 Mouse 3  Mouse 1 Mouse 2 Mouse 3 
Conc injected NSPT, mM 1  6 6 6  6 6 6 
Conc injected NSPT, mg/mL 1 0.59  3.53 3.53 3.53  3.53 3.53 3.53 
Injection volume, mL 0.1  0.1 0.1 0.1  0.2 0.25 0.25 
Mouse weight, g 18.5  17 17.5 18  19.2 19.3 18.7 
Injected NSPT mg/mouse 0.06  0.35 0.35 0.35  0.71 0.88 0.88 
Injected dose, mg/kg 3.21  20.79 20.19 19.63  36.81 45.77 47.24 
Blood concentration, µM 2 90.91  541.17 541.17 541.17  992.14 1190.56 1190.56 
1
 Calculated based on 593.58 g/mol molar mass of Niclosamide stearate. 951 
2




Table 1. Parameters for Dose escalation study.  The concentration that the Injected Dose 954 
achieves in the C57BL/6 mouse in units of M is calculated based on a 1ml mouse blood 955 
volume. (NOTE: actual plasma volumes/mouse were based on 60 mL/kg, and so were 1.08, 0.99, 956 
1.02, 1.05, 1.12, 1.13, 1.09 mL) (Riches, Sharp et al. 1973, NC3Rs 2019). 957 
 958 
9. Figure Legends 959 
FIGURE 1. Nanoparticle size and the Composition and Structure of the NSPT. A) 960 
Diameters of nanoparticles measured by DLS directly after making using the rapid solvent 961 
injection method.  The particle size (hydrodynamic diameter) was measured using a Dynamic 962 
Light Scattering instrument (Dyna Pro Nanostar, Wyatt Technology). For all 5 of the 50 mg/kg 963 
treatments was 45 ± 5 nm. As shown the DLS algorithm reports three peaks with % Intensity 964 
values: Peak 1: 2.2 nm (2.3%); Peak 2: 30.8 nm (92.2%); Peak 3: 414.4 nm (5.4%). Mean PDI 965 
for Treatment 1 was 0.303. Shown is the DLS intensity distribution for Treatment 1 of the high 966 
dose (50 mg/kg) samples used for D418 tumors.  DLS intensity distributions, peaks, PDI, and % 967 
intensity for treatments 1 to 5 are shown in Supplemental Information Figure S1. B) 968 
Schematic representation drawn to scale, of an NSPT. The core is represented as an isotropic 969 
liquid or solid amorphous material of niclosamide stearate with a lipid monolayer of DSPC:Chol 970 
(45:50 mol:mol) providing a mechanical barrier to water penetration and protein binding, and a  971 
5 mol% of DSPE-PEG
2000
 providing a steric barrier to protein binding around the niclosamide 972 
stearate core that is depicted here as an amorphous core (it may instead be crystalline, but that is 973 
yet to be fully confirmed). Also shown are the dimensions of each of the chemical structures 974 
(van der Waals surface) and size of the components, DSPC (3.1 nm), Chol 1.9 nm), DSPE-975 
PEG
2000
, (DSPE 3.1 nm, and PEG 3.6 nm, making a total size of 6.7 nm) and niclosamide 976 
stearate (3.0 nm) 977 
 978 
FIGURE 2.  In-vitro stability and Pharmacokinetics of the Niclosamide Stearate Prodrug 979 
Therapeutic (NSPT) .  A) Concentration of niclosamide (NIC) generated by hydrolysis and/or 980 
enzymolysis of niclosamide stearate (NS) core within NSPT (lipid coated nanoparticles) in PBS, 981 
(t1/2 = 17 days) and mouse and human plasma ((t1/2 = >24hrs) ) measured versus time for 0.25, 1, 982 
4, and 24 hrs at 37
o
C, starting with 1.8 mM NS as NSPT.  This is equivalent to the estimated 983 
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mg/kg niclosamide equivalent). B) Concentration of NS and NIC in plasma measured over 24 h 985 
after i.v. administration of 50 mg/kg NSPT (27 mg/kg niclosamide equivalent). The Area Under 986 
the Curves (AUC) are: NS, 3560h*ug/ml; and NIC, 690h*ug/ml.  Plotted also are published NIC 987 
dosed i.v. at 2mg/kg by dissolving the niclosamide in a mixture of dimethyl sulfoxide (DMSO)/ 988 
cremophor EL/water (3/15/82 v/v/v) in rat data (dashed) for illustration purposes (Chang et al. 989 
2006) showing an AUC of only 1.4 h*ug/ml and a half-life of  6.7 ± 2.0 hr.  Inset is the log-990 
linear plot illustrating the similar half-life for both NS (5 hrs) and NIC (5.5hrs) by a single-order 991 
decay.  992 
 993 
FIGURE 3.  In Vitro cell viability, proliferation, apoptosis and Western blots 994 
A) Dose-response assays for niclosamide in DMSO and NSPTs in canine OS cell lines: 143B 995 
and D418. (See Supplementary Figure S2A for individual plots of all 8 cell lines).  B) 996 
Cumulated IC50 values for all human (143B, MG63, U2OS, SaOS2) and canine (D417, Moresco, 997 
Abrams, D17) cell line by treatment. C) Time- and dose- response assays of NSPTs on NLS 998 
mCherry labeled 143B human and D418 canine OS cells, representing: phase confluence % 999 
(C(i)); red object fluorescence cell count (C(ii)); and green object fluorescence area (C(iii)) 1000 
representative of caspase 3/7-dependent apoptotic events. (See Supplementary Figure S2B and 1001 
C for individual plots of all 8 cell lines). D) Cross plots for D(i) 143B and D (ii) D418 of Total 1002 
red area and Normalized green fluorescent intensity vs NSPT concentration at 96 hrs. (See 1003 
Supplementary Figure S2D for individual plots of all 8 cell lines). E) Western blot signaling 1004 
pathway analysis performed on (i) human OS cell line 143B and (ii) patient-derived canine 1005 
xenograft (D418) Cells were incubated with 20 µM NSPTs for 0-8 hours. (iii), Western blots 1006 
performed on the 143B cell line after no treatment or treatment with niclosamide-stearate 1007 
nanoparticles (20 M) for 24 hours. (See Supplementary Figure S3A and B for individual plots 1008 
of all 8 cell lines).Cell lysates were separated into cytoplasmic and nuclear fractions using 1009 
ThermoFisher’s NE-PER kit and samples were run on 4-12% BT gels, transferred to PVDF 1010 
membranes and stained with antibodies to -catenin, tubulin (cytoplasmic loading control) and 1011 
Histone H3 (nuclear loading control).  1012 
 1013 
FIGURE 4. The ex vivo Pulmonary Metastasis Assay (PuMA). (A and D) Representative 1014 
fluorescence images of pulmonary metastasis assay at 5X magnification with BF and EGFP filter 1015 
sets (A) in human 143B and (B) in canine D418 from days 1, 5, and 10 following exposure to 1016 
PBS, doxorubicin, and NSPTs. Exposure time was determined daily by PBS control fluorescence 1017 
intensity. Dosing was done on the first day.  (B and E) Quantification of lung tumor burden (B) 1018 
in 143B, and (E) in D418 using mean fluorescence area over total lung area. (C and F) Time-1019 
dependent change in treatment group lung tumor burden normalized to daily PBS lung tumor 1020 
burden for (C) 143B and (F) D418.  Note: these graphs represent normalized lung tumor burden. 1021 
They are normalized to PBS lung tumor burden for each time point. The treatment groups are 1022 
always referenced to that day’s PBS. That’s why the PBS graph appears to not change while the 1023 
treatment decreases. ns. **p<0.01 vs. PBS, ***p<0.001 vs. PBS, #p<0.05 vs. Dox 10 µM. 1024 
 1025 
FIGURE 5. Low dose (0.59mg/kg) in vivo study.  6-week old SCID/beige mice were 1026 
inoculated on Day 0 with luciferase-labeled 143B (5 x 10
5
 OS cells and treated with 0.59mg/kg 1027 
weekly starting on Day1. Animals were injected weekly with 200l of PBS or 200l of a 100 1028 
M suspension NSPTs, or Doxorubicin, weekly at 1.2 mg/kg in PBS intraperitoneal. A) 1029 
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Luminescent images for PBS, NSPT, and Dox versus time in a typical example. B) Average 1030 
bioluminescence tumor burden in units of p/s/cm2/sr for each treatment group versus days post 1031 
inoculation for the first 17 days (error bars indicate standard error). C) Kaplan Meier survival 1032 
curves for each treatment group with log-rank test comparing PBS, NSPT, doxorubicin, and 1033 
combination therapy (NSPT + Dox). Mice were also observed for signs of adverse effects 1034 
including anorexia, dehydration, dyspnea, diarrhea, lethargy, or decreased grooming activity. D) 1035 
Average change in weight by treatment group versus days post inoculation for the first 39 days. 1036 
E) Schematic showing how Luciferase positive tumor cells were delivered to mice by tail-vein 1037 
injection, adapted from Mendoza et al, (Mendoza, Hong et al. 2010).  Statistical significance: 1038 
*p<0.05 vs. PBS; #p<0.05 vs. Doxorubicin; *p<0.05 PBS vs. Doxorubicin; $p<0.05 NSNP vs. 1039 
Doxorubicin; #p<0.05 PBS vs. NSPT+Doxorubicin; %p<0.05 NSNP vs. NSPT+Doxorubicin.  1040 
 1041 
FIGURE 6. High does (50 mg/kg) in vivo study. 6-week old SCID/beige mice were inoculated 1042 
on Day 0 with 5 x 10
5
 luciferase-labeled D418 OS cells and treated with 100 L of PBS, 100 L 1043 
of a (e.g.) 8.44 mM suspension of NSPTs dosed weekly starting on Day 1 or i.p. doxorubicin 1044 
1.2mg.kg (MTD) weekly.  A) Luminescent images for PBS, NSPT and Dox versus Day after 1045 
inoculation (Note: first dose taken up by the entrapped OS cells).  B) Average bioluminescence 1046 
tumor burden for each treatment group versus time (grey PBS, red Dox, teal-green NSPT) with 1047 
error bars indicating standard error.  C) Average change in weight by treatment group versus 1048 
days post inoculation for the first 32 days. Mice were also observed for signs monitored included 1049 
anorexia, dehydration, dyspnea, diarrhea, lethargy, or decreased grooming activity.  1050 
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10. Figures  1051 
 1052 
FIGURE 1.  1053 
 1054 
 1055 
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FIGURE 3.   1059 
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 1061 
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FIGURE 5. 1065 
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 1067 
FIGURE 6. 1068 
 1069 
B. 143B Metastatic Burden 0.18mg/kg :
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